Construction of Scientific Management Mode of "Adjuvant Drugs" Based on Evidence-Based Medicine

This study aimed to standardize the clinical application of adjuvant drugs and control unreason-able increase in drug costs. Management measures were formulated for utilization by promoting rational use drugs. The efficacy economics same types compared provide a scientific reference selection. In 2018, total cost decreased 7.4117 million renminbi with that 2015. first half 2019, proportion revenue from 10.77 % period From 2015 per capita gradually this resulted savings 568.41 renminbi. Through administrative intervention, prescription review, information management pharmaco-economic evaluation, system was established reduce their cost. can avoid unnecessary expenses patients effective values hospitals.